Impact of vaccination programs on the incidence of meningococcal infections
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20243671Keywords:
Meningococcal infections, Vaccination programs, Herd immunity, Mass gatherings, Public healthAbstract
Meningococcal infections, caused by Neisseria meningitidis, are a major cause of morbidity and mortality worldwide, particularly among young children, adolescents, and immunocompromised individuals. Vaccination programs have been instrumental in reducing the incidence of meningococcal disease by targeting the most common serogroups responsible for infections, including A, B, C, W, and Y. The introduction of conjugate and quadrivalent vaccines has resulted in significant declines in infection rates across various regions, demonstrating both direct protection for vaccinated individuals and the establishment of herd immunity, which benefits the entire population by reducing transmission. In mass gatherings, such as the annual Hajj pilgrimage, the risk of meningococcal disease outbreaks is high due to the large influx of people from diverse geographical locations. Mandatory vaccination policies have been implemented to prevent such outbreaks, particularly with quadrivalent vaccines that target the most prevalent serogroups. This has proven highly effective in preventing the spread of meningococcal disease both during and after these events. However, challenges remain in achieving global vaccination coverage, particularly in low- and middle-income countries where healthcare infrastructure and vaccine affordability can be limiting factors. Additionally, vaccine hesitancy driven by cultural and social factors continues to impede vaccination efforts in some regions. Addressing these challenges through enhanced public health campaigns, financial support for vaccination programs, and targeted strategies such as school-based vaccination initiatives is critical to increasing coverage. As meningococcal vaccination programs continue to evolve, ongoing surveillance, public education, and global collaboration will be necessary to sustain progress in controlling this potentially devastating disease. The impact of vaccination extends beyond individual protection, offering community-wide benefits and significantly reducing the global burden of meningococcal infections.
Metrics
References
Pollard AJ, Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine. 2001;19(11-12):1327-46.
Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines. 2009;8(7):851-61.
Wilder-Smith A, Memish Z. Meningococcal disease and travel. Int J Antimicrobial Agents. 2003;21(2):102-6.
Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev. 2007;31(1):3-14.
Zahlanie YC, Hammadi MM, Ghanem ST, Dbaibo GS. Review of meningococcal vaccines with updates on immunization in adults. Human Vaccines Immunotherapeutics. 2014;10(4):995-1007.
Al-Tawfiq J, Memish Z. The Hajj: updated health hazards and current recommendations for 2012. Eurosurveillance. 2012;17:41.
Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM, Maiden MC. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immunity. 2004;72(10):5955-62.
Trotter C, Gay N, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect. 2006;134(3):556-66.
MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. Morb Mort Wkly Rep. 2015;64(41):1171-6.
Huels J, Clements K, McGarry L, Hill G, Wassil J, Kessabi S. Modelled evaluation of multi-component meningococcal vaccine (Bexsero®) for the prevention of invasive meningococcal disease in infants and adolescents in the UK. Epidemiology & Infection. 2014;142(9):2000-12.
Ramsey M, Andrews N, Trotter C, Kaczmarski E, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326(7385):365-6.
Kristiansen PA, Jørgensen HJ, Caugant DA. Serogroup A meningococcal conjugate vaccines in Africa. Expert Rev Vaccines. 2015;14(11):1441-58.
Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014;349:g5725.
Lingani C, Bergeron-Caron C, Stuart JM, Katya F, Mamoudou HD, Olivier R, et al. Meningococcal meningitis surveillance in the African meningitis belt, 2004-2013. Clin Infect Dis. 2015;61(5):S410-5.
Jentes ES, Poumerol G, Gershman MD, David RH, Johan L, Rosamund FL, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. The Lancet Infect Dis. 2011;11(8):622-32.
Harris CM, Wu HM, Li J, Irene HH, Adria L, Elizabeth Z, et al. Meningococcal disease in patients with human immunodeficiency virus infection: a review of cases reported through active surveillance in the United States, 2000–2008. Open Forum Infect Dis. 2016;3(4):ofw226.
Kim TH, Johnstone J, Loeb M. Vaccine herd effect. Scand J Infect Dis. 2011;43(9):683-9.
Greenwood B. The contribution of vaccination to global health: past, present and future. Philosophical Transactions of the Royal Society B: Biological Sci. 2014;369(1645):20130433.
Larson HJ, Schulz WS, Tucker JD, Smith DM. Measuring vaccine confidence: introducing a global vaccine confidence index. PLoS Curr. 2015;7:ecurrents.outbreaks.ce0f6177bc97332602a8e3fe7d7f7cc4.
MacNeil JR, Cohn AC, Zell ER, Susanna S, Elaine M, Thomas C, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatric Infectious Disease J. 2011;30(6):451-5.
